A DYNAMIC APPROACH TO

CLINICAL RESEARCH

LEADING THE LARGEST CELLULITE CLINICAL TRIALS IN THE US

Designing an innovative treatment for cellulite began with pursuing the bold research that exemplifies our philosophy of redefining scientific artistry.

We completed the phase 3 studies for our cellulite injectable in two identical, multicenter, randomized, double-blind, placebo-controlled studies called RELEASE trials 1 and 2.

845

WOMEN

RELEASE TRIAL 1: 423

RELEASE TRIAL 2: 422

18+

AGE RANGE

(years)

Each patient received up to 3 treatments, occurring ~21 days apart, of the cellulite injectable or placebo. At Day 71, the differences in physician- and patient-reported responses on the photonumeric cellulite severity scale (PCSS) at the outset and conclusion of the trial were evaluated.

Day

01

Injection one

Day

22

Injection two

Day

43

Injection three

Day

71

Observation

PRIMARY ENDPOINT

Physicians and patients were asked, independently, to assess the appearance of cellulite in the target buttock on a photonumeric scale before and after treatment.

We developed this 5-level scale with third-party psychometric experts to describe the severity of the appearance of cellulite. This scale ranges from 0 to 4, in increasing order of severity.

PCSS

Photonumeric Cellulite Severity Scale

Physician-reported improvement in PCSS score

Patient-reported improvement in PCSS score

The primary endpoint was the percentage of subjects who had a 2-level improvement on both the patient- and physician-reported scales.

2

We published our initial findings from phase 3 studies.

Examine our data

BE THE FIRST TO HEAR OUR NEWS

There’s a new era of aesthetic innovation on the horizon—join us as we redefine scientific artistry.

Please enter a valid state.

Please enter a valid zip code.

By submitting my information, I agree to the Terms of Use.

We’re excited to enter this new era with you.

We’ll be in touch soon.

Sorry, we weren’t able to complete your request.

Please try again later.

Thank you for visiting EndoAesthetics.com

Endo does not review or control the content at the site to which this hyperlink connects; therefore, this hyperlink does not constitute an endorsement by Endo of the content of any non-Endo site.

Do you wish to continue?

YES NO

MEET ENDO AESTHETICS AT GAC!

We’re excited to speak with you about how we are designing the first injectable treatment for cellulite.

NPRC-CC-05281/October 2019